TP53 and breast cancer: The authors of the publication in [55] reported that, in response to doxorubicin-based chemotherapy in BC ER-positive and TP53 wild-type (WT), the suppression of the p53 apoptotic response by the ER would lead to tumor cell senescence and resistance to treatment.